Andreas Strüngmann
| Date of birth | 16.02.1950 |
| Place of birth | Mühlheim an der Ruhr |
Connections
Andreas Strüngmann
- holds shares -
BioNTech
Andreas and Thomas Strüngmann took part in the company Biontech founded in 2008 with start-up capital of around $ 180 million.
In July 2020 they were about 50 percent of Biontech.
The rapid increase in Biontech's stock value in 2020 after the development of the COVID 19 vaccine BNT162B2 led to a significant increase in assets of the Strüngmann twins.
In July 2020 they were about 50 percent of Biontech.
The rapid increase in Biontech's stock value in 2020 after the development of the COVID 19 vaccine BNT162B2 led to a significant increase in assets of the Strüngmann twins.
The twins Andreas and Thomas Strüngmann are estimated that around 50% of the shares in Biontech.
Andreas Strüngmann
- Twin brothers -
Thomas Strüngmann
Andreas and Thomas Strüngmann are identical twins.
WiKipedia [* muss spezifiziert werden *]
Andreas Strüngmann
- founder -
Ernst Strüngmann Institut
No information yet.
Andreas Strüngmann
- founder -
Hexal AG
In 1986 Andreas and Thomas Strüngmann founded Hexal Chemie GmbH & Co Kg.
In February 2005, the founders sold Hexal AG to the Swiss Novartis Group; There Hexal was integrated into the Sandoz sub -Group.
In February 2005, the founders sold Hexal AG to the Swiss Novartis Group; There Hexal was integrated into the Sandoz sub -Group.